Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 11, 2006, Pages 548-556

  Salgueiro, E ^a   Rubio, T ^a   Hidalgo, A ^a   Manso, G ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Drug safety; Proton pump inhibitors; Spontaneous report

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ABDOMINAL PAIN; ALOPECIA; ANGIONEUROTIC EDEMA; APPLICATION SITE REACTION; ARTHRALGIA; ARTICLE; BILIARY TRACT DISEASE; CONSTIPATION; DIARRHEA; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; DYSPEPSIA; ENDOCRINE DISEASE; EPIDERMOLYSIS; FLATULENCE; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; GYNECOMASTIA; HEPATITIS; HUMAN; JAUNDICE; LIVER DISEASE; LIVER TOXICITY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; PRESCRIPTION; PRURITUS; SKIN APPENDAGE DISEASE; SKIN DISEASE; STOMATITIS; TONGUE DISEASE; URINARY TRACT DISEASE; URTICARIA; VISUAL DISORDER; VOMITING; XEROSTOMIA;

EID: 33750857396     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44548     Document Type: Article

References (44)

1. Alvarez-Requejo A, Carvajal A, Bagaud B, Moride Y, Vega T, Arias LH. Under-reporting ofadverse drug reactions. Estimate based on a spontaneous reporting scheme and sentinel system. Eur J Clin Pharmacol. 1998; 54: 483-488.
2. Anonymous. Grupos terapéuticos y principios activos de mayor consumo en el Sistema Nacional de Salud durante 2004. Inf Ter Sist Nac Salud. 2005; 29: 49-53. Available on: http://www.msc.es/farmacia/infmedic
3. Barsky AJ, Saintfort R, Rogers MP, Barns JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002; 287. 622-627.
4. Carswell CI, Goa KL. Rabeprazole: an update of its use in acid-related disorders. Drugs. 2001; 61: 2327-2357.
5. Carvajal A, Prieto JR, Álvarez A, Martin LH. Aspirin or acetaminophen? A comparison from data collected by the Spanish drug monitoring system. J Clin Epidemiol. 1996; 49: 255-261.
6. Carvajal A, Martín Arias L, Vega E, Garcia Sánchez JA, Martín Rodríguez I, García Ortega P, García del Pozo J. Gastroprotection during the administration of non-steroidal anti-inflammatory drugs. A drug-utilization study Eur J Clin Pharmacol. 2004; 60: 439-444.
7. Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol. 1996; 91: 1749-1757.
8. Christe C, Stoller R, Vogt N. Omeprazole-induced hepatotoxicity? A case report. Pharmacoepidemiol Drug Safe. 1998; 1: S41-S44.
9. Cohen J. Switching omeprazole in Sweden and the United States. Am J Ther. 2003; 10: 370-376.
10. Creutzfeld WC, Blum AL. Safety of omeprazole. Lancet. 1994; 343: 1098.
11. de Silva HJ. Gastrointestinal drugs. In: Aronson JK (ed). Side effects of drugs. Annual 27. Amsterdam: Elsevier; 2004. p. 362-372.
12. Fendrich AM, Shaw M, Sahachtel B, Allgood L, Allgood G, Grender J, Peura D. Self-selection and use patterns of over-the-counter omeprazole for frequent heart-burn. Clin Gastroenterol Hepatol. 2004; 2: 17-21.
13. Goff JS. Lansoprazole: a cause of secretory diarrhea. Am J Gastroenterol. 1998; 93: 2298-2299.
14. Harris BN, West DS, Johnson J, Hong SH, Stowe CD. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan. J Manag Care Pharm. 2004; 10: 449-455.
15. International monitoring of adverse reactions to drugs. Adverse reaction terminology. World Health Organization Collaborating Centre of International Drug Monitoring. Uppsala; 1992.
16. Johnson TJ, Hedge DD. Esomeprazole: a clinical review. Am J Health-Syst Pharm. 2002; 59: 1333-1339.
17. Johnstone D, Berger C, Fleckman P. Acute fulminant hepatitis after treatment with rabeprazole and terbinafine. Arch Intern Med. 2001; 161: 1677-1678.
18. Kivioja A, Linnosmaa I, Vehviläinen A, Voldonen I. Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions. Eur J Pharm Sci. 2004; 21: 171-178.
19. Laporte JR. Ibañez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs. Drug Safe. 2004; 27: 411-420.
20. 2 antagonists and of omeprazole. Pharmacoepidemiol Drug Safe 1998; 7: 233-241.
21. Marchetti F, Gerarduzzi T, Ventura A. Proton pump inhibitors in children: a review. Digest Liver Dis. 2003; 35: 738-746.
22. Martin RM, Kapoor KV Wilton LV Mann RD. Under-reporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. Br Med J. 1998; 317: 119-120.
23. Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol. 2000; 50: 366-372.
24. Mearin F, Balboa A, Zarate N, Cucala M, Malagelada JR. Placebo in functional dispepsia: symptomatic, gastrointestinal motor, and gastric sensorial responses. Am J Gastroenterol. 1999; 84: 116-125.
25. Metz DC, Soffer E, Forsmack CE, Cryer B, Chey W, Bochnek W, Pisegna JR. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiophatic hypersecretion. Am J Gastroenterol. 2003; 98: 301-307.
26. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in nonnuclear dyspepsia: a systematic review and economic analysis. Gastroenterology. 2004; 127: 1329-1337.
27. Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B. Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidermol Drug Safe. 2003; 12: 271-281.
28. Morales-Olivas FJ, Martinez-Mir I, Ferrer JM, Rubio E, Palop V. Adverse drug reactions in children reported by means of the yellow card in Spain. J Clin Epidemiol. 2000; 53: 1076-1080.
29. Reilly JP. Safety profile of the proton pump inhibitors. Am J Health-Syst Pharm. 1999; 56: S11-S17.
30. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001; 96: 656-665.
31. Romero-Gómez M, Otero MA, Suárez-García E, Garcia Díaz E, Fobelo MJ, Castro-Fernández M. Acute hepatitis related to omeprazole. Am J Gastroenterol. 1999; 94: 1119-1120.
32. Schönhöfer PS. Intravenous omeprazole and blindness. Lancet. 1994; 343: 665
33. Schroder-Bernhardi D, Roth K, Dietlein G. Off-laber use of proton pump inhibitors and P-blockers in general practices: an analysis using the Disease Analyzed-mediplus patient database. Int J Clin Pharmacol Ther. 2004; 42: 581-588.
34. Sicras Mainar A, Navarro Artieda R. Ambulatory prescriptions among different health-care levels of a health organization. Med Clin (Bare). 2004; 123: 317-319.
35. Smith JD, Chang KL, Gums JG. Possible lansoprazole-induced eosinophilic syndrome. Ann Pharmacother. 1998; 32: 196-200.
36. Steinjans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW. Lack of pantoprazole drug interactions in man: an uptdated review. Int J Clin Pharmacol Ther. 1996; 34: 243-262.
37. Thompson WG. Placebos: a review of the placebo response. Am J Gastroenterol. 2000; 95: 1637-1643.
38. van Puijenbroek E, Diemont W, van Grootheest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Safe. 2003; 26: 293-301.
39. van Zyl J, van Reusburg C, Vieweg W, Fischer R. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease. Digestion. 2004; 70: 61-69.
40. Vaquero MB. Prescription, dispensation and substitution of prescription forms of omeprazole. Gac Sanit. 2003; 17: 296-301.
41. Viana de Miguel C, Álvarez García M, Sánchez Sánchez A, Carvajal Garcia-Pando A. Lansoprazole-induced hepatitis. Med Clin (Barc). 1997; 108: 599.
42. Wallestein EJ. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Safe. 2001; 24: 233-237.
43. Whitaker M. Proton pump inhibitors in the elderly population. Eur J Gastroenterol Hepatol. 2002; 14: S5-S9.
44. Wilton LV, Key C, Shakir SAW. The Pharmacovigilance of Pantoprazole. The results of postmarketing surveillance on 11,541 patients in England. Drug Safe. 2003; 26. 121-132.